Osteoporosis is a chronic disease in which the bone density and bone mass is reduced to such an extent that the bones and cartilages become more prone to cracks and fractures. In osteoporosis, the microstructure of bones and amount and number of various proteins is depleted, that leads to not only rise in brittleness and porosity of bones but also failure of bones to regenerate. This condition leads to chronic pain and illness, which could be fatal. Osteoporosis drugs market is semi-consolidated market and the demand for various drugs (inclusive of generic and branded) is increasing at a slow pace, due to steady growth in the prevalence of the disease across the globe. This report is focused towards identifying the current scenario as well as the future market potential for osteoporosis drugs globally. The global osteoporosis drugs market is segmented on the basis of drugs classes available for the treatment of osteoporosis, such as, bisphosphonates, RANK ligand inhibitors (denosumab), calcitonin, parathyroid hormone therapy (PTH), selective estrogen receptor inhibitors (SERMs) and others (estrogen therapy and calcium and vitamin D). 
Bisphosphonates is identified as the largest segment, with a share of 48.2% of the total osteoporosis drugs market, as of 2013. Whereas, pipeline drugs is identified as the fastest growing segment growing at a CAGR of 125.2%, during the study period from 2014 to 2020. Rising population of osteoporosis patients across the globe is identified as the major driver of this market, followed by introduction of new drug classes. According to International Osteoporosis Foundation (IOF), every year, osteoporosis causes more than 9 million fractures and bone cracks across the globe. Further, it also stated that, around 200 million women throughout the world are being affected by osteoporosis every year. Thus, increasing prevalence of the disease is considered as an important growth propeller of the market. In addition, introduction of new drug classes to overcome threat of generics and chronic side effects caused by established drugs (brands) is another factor accentuating the growth of osteoporosis drugs market. Recently, new drug classes, such as, parathyroid hormone therapy (PTH) (2008) and denosumab (2010) have been introduced in the market. Due to minimal side effects of the drugs that belong to these classes, the demand and focus of treatment has been shifted towards these treatments. In addition, pipeline products such as, Odanacatib, Romosozumab and BA058-SC are estimated to propel the growth of the market after their regulatory approvals. This growth is likely to observe due to the distinct advantages of these drugs over existing drugs and formulations. The forecast for these products is estimated considering their expected approval and commercialization years.
Geographically, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific and Rest of the World (RoW). Presently, the North American region is the largest market in the world, owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose. However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.
The osteoporosis drugs market is considered as semi-consolidated and is dominated by selective players. More than 63% of the total market share is held by market players such as, Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc. and Novartis International AG. These players, due to their effective products, dominate the entire market. In addition, other players include F. Hoffmann La Roche Ltd., Actavis plc, Teva Pharmaceutical Industries Ltd. and Novo Nordisk A/S. which contributed to the market with their generic formulations.
Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. The osteoporosis drugs market report studies the current scenario as well as the future market potential for osteoporosis drugs globally. The disease overview section of the report provides a brief introduction of osteoporosis along with causes, diagnosis, symptoms and management methodology. The market for osteoporosis drugs has been segmented on the basis of drug classes used to treat the disease. The market for these drug classes has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence, pipeline drug candidates, patents and global impact on sales of the drugs (along with the class) after patent expiry. Based on drug class, the market is divided into bisphosphonates, calcitonin, RANK Ligand Inhibitors (denosumab), parathyroid hormone therapy (PTH), selective estrogen receptor modulators (SERMs) and others (estrogen therapy and vitamin D - calcium). Bisphosphonates is the largest and established drug class. However, the entire class is driven by generic products. Hence, market share of this class is expected to decrease during the forecast period from 2014 to 2020. In addition, new drug classes such as RANK Ligand Inhibitors and PTH are considered as important contributors in the market. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are also forecasted from the expected year of approval. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2014 to 2020.
Geographically, the osteoporosis drugs market has been segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2012 to 2020, along with the CAGR (%) for the forecast period 2014 to 2020. The geographical study is mainly based on various regional parameters, such as, prevalence of the disease in particular region, technological utilization, presence of key players, and other domestic factors. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis, market attractiveness analysis, event impact analysis and value chain analysis. These different analyses would provide a thorough understanding about the market from its past, present and future perspectives and help market players to design effective business strategies. The market overview section of the report also includes the competitive landscape of the market wherein market share analysis of leading players in the global osteoporosis drugs market, in terms of percentage share in 2013, has been discussed. This analysis would help established players to penetrate the market. Market attractiveness analysis would help the market player to understand the level of attractiveness of various regions of the world, estimated on various parameters such as size, raw materials, competition and others.
A list of recommendations has also been included for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report concludes with the profiles of major players in the global osteoporosis drugs market such as Actavis plc, Amgen, Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd., Merck & Co, Inc., Novartis International AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. 
  • Osteoporosis Drugs Market, by Drug Class
    • Bisphosphonates
    • Parathyroid Hormone Therapy (PTH) Drugs
    • Selective Estrogen Receptor Modulators (SERMs)
    • RANK Ligand Inhibitors
    • Calcitonin
    • Others (Vitamin D, Calcium)
    • Pipeline Analysis
  • Osteoporosis Drugs Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Osteoporosis Drug Market

Buy Now